Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$4.6M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$233M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | Oct 4, 2024 | Sell | 1,030,589 | $50.0016 | $52M |
| Sturge Simon | Oct 4, 2024 | Sell | 171,000 | $53.72 | $9.2M |
| BIOTECHNOLOGY VALUE FUND L P | Oct 4, 2024 | Sell | 836,862 | $50.0016 | $42M |
| BIOTECHNOLOGY VALUE FUND L P | Oct 4, 2024 | Sell | 132,549 | $50.0016 | $6.6M |
| Santos da Silva Jorge | Feb 29, 2024 | Sell | 4,740 | $55.89 | $260,000 |
| Santos da Silva Jorge | Feb 28, 2024 | Sell | 56,065 | $55 | $3.1M |
| Reich Kristian | Feb 28, 2024 | Sell | 31,910 | $55 | $1.8M |
| Reich Kristian | Feb 28, 2024 | Sell | 28,090 | $55 | $1.5M |
| Santos da Silva Jorge | Feb 27, 2024 | Sell | 62,810 | $55 | $3.5M |
| Reich Kristian | Feb 27, 2024 | Sell | 29,491 | $55 | $1.6M |
| Reich Kristian | Feb 27, 2024 | Sell | 29,431 | $55 | $1.6M |
| Santos da Silva Jorge | Feb 21, 2024 | Sell | 1,125 | $55.27 | $62,000 |
| Reich Kristian | Feb 21, 2024 | Sell | 569 | $55.3 | $31,000 |
| Reich Kristian | Feb 21, 2024 | Sell | 509 | $55.31 | $28,000 |
| Reich Kristian | Feb 20, 2024 | Sell | 10,000 | $57.43 | $570,000 |
| Santos da Silva Jorge | Feb 20, 2024 | Sell | 20,000 | $57.44 | $1.1M |
| Reich Kristian | Feb 16, 2024 | Sell | 10,000 | $60.15 | $600,000 |
| Bodenstedt Matthias | Dec 20, 2023 | Sell | 5,264 | $58.34 | $310,000 |
| Bodenstedt Matthias | Dec 19, 2023 | Sell | 94,736 | $59.22 | $5.6M |
| Cormorant Asset Management, LP | Oct 5, 2023 | Buy | 58,839 | $59.8973 | $3.5M |
| Cormorant Asset Management, LP | Oct 4, 2023 | Buy | 67,814 | $57.3188 | $3.9M |
| Cormorant Asset Management, LP | Oct 3, 2023 | Buy | 150,487 | $57.252 | $8.6M |
| Cormorant Asset Management, LP | Oct 2, 2023 | Buy | 74,911 | $57.37 | $4.3M |
| Chen Bihua | Jun 30, 2023 | Buy | 800,000 | $50 | $40M |
| Chen Bihua | Jun 26, 2023 | Buy | 66,087 | $43.3 | $2.9M |
| Chen Bihua | Jun 26, 2023 | Buy | 61,042 | $42.12 | $2.6M |
| Chen Bihua | Jun 26, 2023 | Buy | 59,787 | $49.82 | $3M |
| Chen Bihua | Jun 26, 2023 | Buy | 50,642 | $41.03 | $2.1M |
| Chen Bihua | Jun 26, 2023 | Buy | 38,623 | $39.87 | $1.5M |
| Chen Bihua | Jun 26, 2023 | Buy | 37,783 | $48.93 | $1.8M |
| Chen Bihua | Jun 26, 2023 | Buy | 31,558 | $44.23 | $1.4M |
| Chen Bihua | Jun 26, 2023 | Buy | 21,823 | $53.98 | $1.2M |
| Chen Bihua | Jun 26, 2023 | Buy | 18,949 | $54.92 | $1M |
| Chen Bihua | Jun 26, 2023 | Buy | 17,662 | $50.77 | $900,000 |
| Chen Bihua | Jun 26, 2023 | Buy | 10,946 | $44.93 | $490,000 |
| Chen Bihua | Jun 26, 2023 | Buy | 10,593 | $39.17 | $410,000 |
| Chen Bihua | Jun 26, 2023 | Buy | 8,697 | $52.01 | $450,000 |
| Chen Bihua | Jun 26, 2023 | Buy | 4,725 | $52.81 | $250,000 |
| Chen Bihua | Jun 26, 2023 | Buy | 3,755 | $38.18 | $140,000 |
| Chen Bihua | Jun 26, 2023 | Buy | 1,894 | $56.89 | $110,000 |
| Chen Bihua | Jun 26, 2023 | Buy | 1,481 | $36.91 | $55,000 |
| Chen Bihua | Jun 26, 2023 | Buy | 1,453 | $55.83 | $81,000 |
| Chen Bihua | Jun 26, 2023 | Buy | 1,302 | $58.98 | $77,000 |
| Chen Bihua | Jun 26, 2023 | Buy | 417 | $60.21 | $25,000 |
| Chen Bihua | Jun 26, 2023 | Buy | 295 | $57.63 | $17,000 |
| Chen Bihua | Jun 26, 2023 | Buy | 139 | $63.85 | $8,900 |
| Chen Bihua | Jun 26, 2023 | Buy | 136 | $62.2 | $8,500 |
| Chen Bihua | Jun 26, 2023 | Buy | 95 | $64.44 | $6,100 |
| Chen Bihua | Jun 26, 2023 | Buy | 85 | $72.46 | $6,200 |
| Chen Bihua | Jun 26, 2023 | Buy | 16 | $65.32 | $1,000 |
| Chen Bihua | Jun 26, 2023 | Buy | 15 | $70.62 | $1,100 |
| Chen Bihua | Mar 21, 2023 | Buy | 238,511 | $21.7013 | $5.2M |
| Chen Bihua | Mar 20, 2023 | Buy | 446,881 | $19.3639 | $8.7M |
| Chen Bihua | Mar 20, 2023 | Buy | 78,008 | $21.0836 | $1.6M |
| Chen Bihua | Mar 20, 2023 | Buy | 63,700 | $20.4207 | $1.3M |
What's the latest insider transaction for MoonLake Immunotherapeutics?
The most recent insider transaction for MoonLake Immunotherapeutics was conducted by BIOTECHNOLOGY VALUE FUND L P, who sold 1,030,589 shares on October 4, 2024 at a price of $50.00 per share.
Which insider bought the most MLTX stock over the last two years?
Chen Bihua has bought the most MLTX stock in the last 2 years, with a total value of $77M.
Which insider has sold the most MLTX stock over the last two years?
BIOTECHNOLOGY VALUE FUND L P has sold the most MLTX stock in the last 2 years, with a total value of $100M.
What is the total value of insider transactions for MoonLake Immunotherapeutics (MLTX) in the last 2 years?
The total value of insider transactions for MoonLake Immunotherapeutics in the last 2 years is negative, amounting to -$33M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on MoonLake Immunotherapeutics' market confidence?
Over the last 2 years, insider transactions for MoonLake Immunotherapeutics have predominantly involved purchasing shares, indicating a strong confidence among insiders in the company's future prospects. This trend of more purchases than sales could be a positive signal to potential investors about the insiders' view on the company's valuation and growth potential.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
